Sargent Investment Group LLC purchased a new stake in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 541,500 shares of the company's stock, valued at approximately $442,000. Sargent Investment Group LLC owned 0.91% of Lucid Diagnostics as of its most recent filing with the SEC.
Analyst Ratings Changes
A number of research analysts have commented on the company. Cantor Fitzgerald decreased their price target on Lucid Diagnostics from $3.00 to $2.00 and set an "overweight" rating on the stock in a research note on Friday, November 15th. Canaccord Genuity Group reissued a "buy" rating and issued a $3.00 price target on shares of Lucid Diagnostics in a research report on Thursday, November 14th. Needham & Company LLC reaffirmed a "buy" rating and set a $2.50 price target on shares of Lucid Diagnostics in a research report on Thursday, November 14th. Finally, Ascendiant Capital Markets dropped their price objective on shares of Lucid Diagnostics from $7.25 to $7.00 and set a "buy" rating on the stock in a research note on Monday, December 9th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Lucid Diagnostics currently has a consensus rating of "Buy" and a consensus target price of $3.63.
Check Out Our Latest Analysis on Lucid Diagnostics
Lucid Diagnostics Stock Performance
Lucid Diagnostics stock traded up $0.10 during trading hours on Friday, reaching $1.07. 781,608 shares of the stock were exchanged, compared to its average volume of 194,222. Lucid Diagnostics Inc. has a 52-week low of $0.63 and a 52-week high of $1.40. The stock has a market cap of $63.49 million, a P/E ratio of -0.94 and a beta of 1.49. The firm's 50 day moving average is $0.85 and its 200 day moving average is $0.86.
Lucid Diagnostics Company Profile
(
Free Report)
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Featured Stories
Before you consider Lucid Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.
While Lucid Diagnostics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
